triple negative breast cancer

A Spark Of Good News For Precision Oncology In Breast Cancer
A Spark Of Good News For Precision Oncology In Breast Cancer
Forbes
AstraZeneca
triple negative breast cancer
AZD5363
precision medicine
Flag link:
Roche’s Tecentriq gets fast review in triple negative breast cancer
Roche’s Tecentriq gets fast review in triple negative breast cancer
Pharmaforum
Roche
Genentech
Tecentriq
Celgene
Abraxane
FDA
triple negative breast cancer
Flag link:
Benefit of Roche's Tecentriq looks limited in breast cancer
Benefit of Roche's Tecentriq looks limited in breast cancer
Biopharma Dive
Roche
Tecentriq
breast cancer
triple negative breast cancer
Flag link:
Trovagene Receives Orphan Drug Designation for Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Trovagene Receives Orphan Drug Designation for Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
CP Wire
TrovaGene
Onvansertib
AML
mCRPC
non-Hodgkin lymphoma
triple negative breast cancer
Flag link:
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
CP Wire
Immunomedics
FDA
sacituzumab govitecan
triple negative breast cancer
Flag link:
Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival
Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival
Endpoints
Roche
Tecentriq
Genentech
triple negative breast cancer
Celgene
Abraxane
Flag link:
OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial
OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial
Drug Delivery Business News
OncoSec Medical
Merck
ImmunoPulse IL-12
Keytruda
triple negative breast cancer
Flag link:
Celldex's highly anticipated breast cancer drug fails to hit the mark in a midstage trial
Celldex's highly anticipated breast cancer drug fails to hit the mark in a midstage trial
Motley Fool
Celldex Therapeutics
triple negative breast cancer
glemba
Flag link:
Seattle Genetics chalks up first clinical trial success in solid tumors
Seattle Genetics chalks up first clinical trial success in solid tumors
Fierce Biotech
Seattle Genetics
clinical trials
solid tumors
SGN-LIV1A
triple negative breast cancer
Flag link:
Immunomedics Kicked Out of Prestigious ASCO Cancer Conference
Immunomedics Kicked Out of Prestigious ASCO Cancer Conference
TheStreet.com
Immunomedics
triple negative breast cancer
ASCO 2016
IMMU-132
Flag link:
Roche adds another positive snapshot for its PD-L1 checkpoint star 'atezo'
Roche adds another positive snapshot for its PD-L1 checkpoint star 'atezo'
Fierce Biotech
atezolizumab
Roche
PD-L1
triple negative breast cancer
Flag link:
Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab
Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab
Yahoo
Amgen
Roche
triple negative breast cancer
Talimogene Laherparepvec
atezolizumab
colorectal cancer
Flag link:
Medivation Poised To Expand As Xtandi Shows Efficacy In Advanced Triple Negative Breast Cancer
Medivation Poised To Expand As Xtandi Shows Efficacy In Advanced Triple Negative Breast Cancer
Seeking Alpha
Medivation
Xtandi
triple negative breast cancer
breast cancer
Flag link: